EP4505999A1 — Probenecid formulations
Assigned to Panntherapi · Expires 2025-02-12 · 1y expired
What this patent protects
The present invention relates to a core-shell particulate formulation presenting a core comprising probenecid in an amount ranging from 10% to 70% in weight relative to the total weight of the core, in association with at least one pharmaceutically acceptable excipient, wherein t…
USPTO Abstract
The present invention relates to a core-shell particulate formulation presenting a core comprising probenecid in an amount ranging from 10% to 70% in weight relative to the total weight of the core, in association with at least one pharmaceutically acceptable excipient, wherein the core is coated with a shell coating composition comprising triethyl citrate, a mineral charge, polyvinyl acetate, polyvinylpyrrolidone and sodium lauryl sulfate, characterized in that the weight ratio of polyvinyl acetate on polyvinylpyrrolidone ranges from 1.5 to 4.
Drugs covered by this patent
- Col-Probenecid (probenecid) · Pfizer Inc.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.